In early October, FCB Health Network proudly launched #WhyVote, a non-partisan campaign that uses the power of storytelling to inspire and empower Americans to vote. On October 30, FCB Health Network partnered with Black Rock Coalition and Club House Global to host the apex of the #WhyVote initiative’s 2020 efforts: #WhyVote Live – A Virtual Pep Rally to the Polls.
Ed Hudson, managing director at Create Health, discusses the increasing importance of brand in pharma – especially in light of increased competition.
Outcome Health announced the launch of Who Saves Me?, a campaign to bring awareness to the overwhelming percentage of physicians who quietly suffer from burnout and mental health struggles.
W2O announced the creation of Hū, the first-of-its kind Patient Activation Organization (PAO).
With $29 million in the company’s pocket, biotech Libra Therapeutics launched to take on neurodegenerative disease, with three pre-clinical programs ready to roll.
Progentec Diagnostics Inc. launched a novel blood test to determine the likelihood that a patient with systemic lupus erythematosus (commonly known as both SLE and lupus) will experience an immunologic disease flare during the coming 12 weeks.
MJH Life Sciences™ Launches COVID-19 Coalition — Alliance of renowned thought leaders to assemble biweekly to keep health care professionals abreast of emerging COVID-19 science and news. September 10, 2020 11:46 AM Eastern Daylight Time CRANBURY, N.J.–(BUSINESS WIRE)–MJH Life Sciences™, the privately owned health care media company, is pleased to officially announce […]
Fingerpaint, a full-service health and wellness marketing agency with five offices across the United States and almost $80 million in revenue, announced the creation of the SHIFT Performance Center of Excellence and the launch of its proprietary Actionable Intelligence Engine.
Clinical diagnostics company Novacyt, one of many healthcare companies whose shares have surged during the pandemic, launched a test to differentiate between Covid-19 and common winter diseases.
ATAI Life Sciences launched EmpathBio, a wholly owned subsidiary focused on developing derivatives of 3,4-methylenedioxy-methamphetamine for the treatment of post-traumatic stress disorder (PTSD).